Delivery Order SPE2DB22D2006-SPE2DB25FW0GN
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,644.62 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on July 25, 2025, with a completion date of July 28, 2025. This is a firm fixed-price, non-competitive delivery order with no set-aside designation, issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The award represents a standard pharmaceutical procurement supporting the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $1,826.12 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors. This firm fixed price, competitively awarded delivery order was issued on August 28, 2025, with an ultimate completion date of August 29, 2025. The contract represents a non-set-aside procurement, indicating open competition among qualified vendors. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, where the place of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,613.98 on September 5, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and a completion date of September 8, 2025. The product will be performed and sourced from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order operates under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,632.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 mL pen injectors on August 6, 2025, with completion expected by August 7, 2025. This is a non-set-aside competitive award placed to the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a relatively small transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio, reflecting the company's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,888.99 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and represents a continuation of the company's critical role as a pharmaceutical supplier to federal military and healthcare systems. The place of performance...
- The Defense Logistics Agency awarded a delivery order valued at $1,879.15 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on August 22, 2025, with a completion date of August 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a small-value pharmaceutical procurement supporting federal healthcare needs. The product will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a $11,496.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen injectors on September 19, 2025, with completion expected by September 22, 2025. This non-set-aside competitive award was issued from the company's place of performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $2,123.03 to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 ml pen injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order, issued without a set-aside designation, represents a competitively awarded pharmaceutical supply transaction supporting federal medical procurement needs. The product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $8,391.06 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors with an ultimate completion date of August 1, 2025. This firm fixed-price, non-set-aside contract is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio. This delivery...
- The Defense Logistics Agency awarded a $6,044.24 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Mounjaro 5 mg/0.5 ml pen injectors (0.5 ml). The award was made on a firm fixed-price basis with no set-aside designation, indicating competitive selection. The contract specifies a completion date of July 31, 2025, and lists the place of performance as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW0GNDelivery Order
The Defense Logistics Agency awarded a $7,583.88 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a small-value transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, the headquarters location for this major pharmaceutical distributor. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This comprehensive prime vendor agreement enables AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, and medical devices. The company's extensive federal contract portfolio demonstrates its critical role in supporting the Defense Health Agency and other government healthcare systems, with consistent performance on competitively awarded contracts across multiple therapeutic domains.